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Abstract B7 costimulatory molecules are present on antigen-
presenting cells (APCs) and influence intracellular expression
of indoleamine 2,3-dioxygenase (IDO), a molecule with im-
portant immunoregulatory functions. We determined the fre-
quency of activated (CD11b+) monocytes expressing B7-1,
B7-2, B7-H1, and B7-H2 molecules, and that of CD3+ and
CD4+ T cells expressing the corresponding CD28, CTLA-4,
PD-1, and ICOS receptors in peripheral blood samples of 20
healthy adults and 9 SSc and 15 pSS patients using flow
cytometry. We also examined the intracellular expression of
IDO. The expression of CD28 was lower in both SSc and pSS
patients. The frequency of CTLA-4 was increased in pSS. The
expression of ICOS, a stimulator of T cell activation, was
elevated in pSS, but not in SSc, while that of its corresponding
costimulatory molecule, B7-H2, was strongly decreased in
SSc compared to controls. The frequency of PD-1 expressing
T lymphocytes was decreased in both pSS and SSc. The fre-
quency of IDO-expressing APCs, as well as intracellular IDO
content in T cells was higher in pSS than in controls. Our
investigation identified a number of differences in B7
costimulation between SSc and pSS patients which may play
a role in the distinct pathogenesis and clinical features of these
autoimmune disorders.
Keywords Antigen presentation . B7 . ICOS . Indoleamine
2,3-dioxygenase
Introduction
Antigen presentation and costimulation are the initial steps in
the activation of T cells, and the nature and intensity of
costimulatory signals are key determinants of the coordination
of pro- and anti-inflammatory events.
B7 costimulatory molecules are expressed on antigen-
presenting cells (APCs), including dendritic cells and mono-
cytes, and are important regulators of T cell activation, as well
as of cytokine production in T helper cells. Upon the engage-
ment of the T cell receptor (TCR), the costimulatory signal
from B7-1 (CD80) or B7-2 (CD86) via CD28 induces the
production of IL-2 in T cells, thus protecting them from apo-
ptosis and anergy. Both the TCR and CD28 are constitutively
expressed by most naive T cells, enabling them to respond to
the antigen being presented [1]. Without costimulation, the
signal from the TCR induces the tolerance of T cells to their
cognate antigen instead of being activated [2].
Nevertheless, B7 family members mediate not only stimu-
latory, but also inhibitory effects on Tcells [1]. Engagement of
the TCR induces the phosphorylation of cytotoxic T lympho-
cyte antigen 4 (CTLA-4), resulting in its stabilization on the
cell surface. Thereby, CTLA-4 will compete with CD28 for
B7 binding, and because its affinity is higher than that of
CD28, it will block the costimulatory signal, and prevent fur-
ther IL-2 production [3].
Another B7 familymember, B7-H1 or PD-L1, has predom-
inantly, but not exclusively, inhibitory effects on T cells. Its
inhibitory function is carried out by signaling through the
programmed death-1 receptor (PD-1), inducing apoptosis or
anergy of self-reactive T cells [4]. Genetic deletion of PD-1
results in severe autoimmunity due to the loss of peripheral
tolerance of self-reactive T cells [5].
B7-H2 or ICOSL serves as the ligand for inducible
costimulator of Tcells (ICOS), and promotes Tcell activation,
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differentiation, and effector responses [6]. Costimulation
through ICOS can augment induction of both Th1 and Th2
cytokines, including IL-4, IL-10, and INF-γ [7].
Besides the initiation of signal transduction in T lympho-
cytes, ligation of CD80 and CD86 may back-signal into the
APC and modulate their function [8]. For instance, reverse
signaling through CD80 and CD86 after ligation by a soluble
form of CTLA-4 was shown to upregulate the tryptophan
(TRP) catabolic enzyme, indoleamine 2,3-dioxygenase
(IDO) [9]. In the first steps of the kynurenine (KYN) pathway,
TRP is transformed into KYN by IDO. KYN is then further
metabolized by different enzymes. The local depletion of TRP
and the production of proapoptotic TRP metabolites of the
KYN pathway, such as 3-hydroxyanthranilic acid and
quinolinic acid, are among the mechanisms potentially re-
sponsible for the immunosuppressive effects of IDO [10].
KYN and its metabolites suppress effector T cell function
and facilitate their differentiation to regulatory T cells [11].
Since the TRP metabolic pathway is activated by pro-
inflammatory stimuli, the anti-inflammatory effect of KYN
metabolites provides a feedback mechanism in the downreg-
ulation of the immune response (Fig. 1).
Primary Sjögren’s syndrome (pSS) is characterized by
lymphocytic infiltration of the salivary and lacrimal
glands, leading to the destruction of exocrine glands, but
the autoimmune inflammatory process often involves other
organs too. Systemic sclerosis (SSc), also termed sclero-
derma, is characterized by autoimmune activation, micro-
vascular injury, and fibrosis in multiple organs, including
the skin, lung, heart, and gastrointestinal tract. Being
chronic systemic autoimmune diseases, permanent activa-
tion of the adaptive immune system is obvious in both pSS
and SSc [12, 13]. The recognition of the outstanding im-
portance of the costimulatory regulation in many autoim-
mune diseases and in tumor-immunology has lead to high-
ly effective targeted therapies in both fields [14–16].
However, data on the alterations in the expression of
costimulatory molecules and their receptors in pSS and SSc
are very limited. We hypothesize that the degree and the bal-
ance of the expression of the components of the B7 family
member molecules and the consequent alterations in the IDO
pathwaymay significantly determine the differences observed
in the immunopathogenesis of autoimmune rheumatic disor-
ders, included in pSS and SSc. In this study, we therefore
aimed to investigate the prevalence of a major APC subset,
CD11b + activated monocytes expressing CD80, CD86, PD-
L1, and ICOSL costimulatory molecules, and that of CD3+ T
cells and CD4+ T helper cells expressing CD28, CTLA-4,
PD-1, and ICOS, as well as the expression of IDO in these
cell types in pSS and SSc.
Materials and methods
Patients
We enrolled 15 patients with pSS, 9 patients with SSc, and 20
age- and gender-matched healthy individuals. Demographic
and laboratory data are summarized in Table 1.
pSS patients fulfilling American European Consensus
Group (AECG) 2002 [17] or American College of
Rheumatology (ACR) 2012 classification criteria [18] were
included. The following clinical symptoms occurred in pSS
patients’ history: sicca syndrome (100%), labial salivary gland
biopsy positivity for focal lymphocytic sialadenitis with focus
score ≥ 1(80%), blood cytopenia (anemia or leukopenia)
(87%), arthritis (67%), vasculitis (53%), anti-SSA/SSB anti-
body positivity (100%), low C3/C4 complement level (47%),
renal involvement (13%), fever and night sweats (20%),
lymphadenopathy (20%), weight loss (33%), myositis (7%),
and peripheral neuropathy (20%). The EULAR Sjögren’s syn-
drome disease activity (ESSDAI) scores were calculated at the
Fig. 1 B7 co-stimulatory molecules expressed on antigen presenting
cells (APCs), and their stimulatory or inhibitory ligands on T cells.
MHC major histocompatibility complex, TCR T cell receptor, ICOS
inducible costimulator, ICOSL inducible costimulator ligand, CTLA-4
cytotoxic T lymphocyte antigen-4, PD-1 programmed death-1 receptor,
PD-L1 programmed death-1 receptor ligand
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time of sampling [19]. The median ESSDAI score was 2
which is consistent with low disease activity. SSc patients
fulfilled the 2013 ACR/EULAR classification criteria for
scleroderma [20]. Patients were further classified as those with
limited cutaneous SSc or diffuse cutaneous SSc according to
LeRoy et al. [21]. The following clinical symptoms occurred
in SSc patients’ history: Raynaud syndrome (88%), digital
ulcers (33%), interstitial lung disease (66%), pulmonal hyper-
tension (33%), and pericarditis (22%).
Healthy controls had a negative history of rheumatic symp-
toms. No co-morbidities were detected in patients and controls
that could have influenced the investigated parameters, nor
did they take any medication that could have interfered with
the measurements. Written informed consent was obtained
from all subjects, and our study was reviewed and approved
by the ethics committee of the institution.
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were separated
by a standard density gradient centrifugation (FicollPaque,
Amersham Biosciences AB, Uppsala, Sweden), by means of
centrifugation for 25 min, 400g, 22 °C from freshly drawn
blood collected in lithium heparin-treated tubes (BD
Vacutainer, BD Biosciences, San Jose, CA, USA). Cells were
kept at −80 °C in fetal bovine serum containing 10% DMSO
until analysis.
Flow cytometry
After thawing, PBMCs were incubated for 30 min at room
temperature in the dark with the following conjugated an-
tibodies: PerCP-conjugated CD3, PE Cy7-conjugated
CD4, PE-conjugated CD28, APC-conjugated CD152
(CTLA-4), FITC-conjugated CD278 (ICOS) and APC-
Cy7-conjugated CD279 (PD-1)mAbs, or PerCP-
conjugated CD3, PE Cy7-conjugated CD11b, APC-
conjugated CD80 and PE-conjugated CD275 (ICOSL)
mAbs, or PerCP-conjugated CD3, PE Cy7-conjugated
CD11b, APC-conjugated CD86, and PE-conjugated
CD274 (PD-L1) mAbs in separate tubes (BioLegend, San
Diego, CA, USA). After washing, cells were fixed with
fixation/permeabilization solution and treated with perme-
abilization buffer according to the manufacturer’s instruc-
tions (eBioscience, San Diego, CA, USA). They were then
stained with a mouse anti-human IDO monoclonal anti-
body (Millipore, USA) for 30 min at 4 °C in the dark.
After washing, cells were stained with FITC-labeled goat
anti-mouse IgG antibody for 15 min at 4 °C in the dark.
After washing, cells were analyzed on a BD FACSAria
flow cytometer (BD Biosciences) equipped with 488- and
633-nm excitation lasers. Data were processed using the
FACSDiVa software. One hundred thousand cells were re-
corded. The populations of lymphocytes and monocytes
were gated from PBMCs according to Forward Scatter
Characteristics and Side Scatter Characteristics.
Table 1 Clinical characteristics
of patients with SSc and pSS as
compared with healthy controls
Characteristics Healthy SSc patients pSS patients
n = 20 n = 9 n = 15
Age (years) 53 (42–61) 53 (39–65) 52 (36–77)
Gender (male/female) 2/6 2/ 7 1/ 14
Disease duration (years) 11 (1–33) 5 (2–14)
ESR (mm/h) 8 (5–12) 24a (1–53) 27a (7–55)
CRP <2 5.47a (2.0–16.0) 4.8a (2.0–13.8)
Autoantibody positivity:
Anti-SSA and/or anti-SSB 0 15
Anti-Scl-70 5 0
Anti-centromere 2 0
Antirheumatic drugs
Methyl-prednisolone 3 7
Chloroquin 0 10
Methotrexate 1 3
Azathioprin 2 1
Data are expressed as median (interquartile range) for continuous variables and as number for categorical
variables
SSc systemic sclerosis, pSS primary Sjögren’s syndrome, ESR erythrocyte sedimentation rate, CRP C-reactive
protein
a p < 0.05 vs. healthy individuals
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Statistics
Data are expressed as median and interquartile range.
Comparisons between sample populations were made with
the Kruskal-Wallis test. Correlation analyses were performed
using Spearman’s signed ranked tests. p values less than 0.05
were considered significant. Statistics were calculated using
the GraphPad Prism software (version: 5.00, GraphPad
Software Inc., La Jolla, CA, USA).
Results
Cell frequency results are summarized in Table 2.
In case of T lymphocytes, no difference was observed in
the prevalence of CD3+ CD28+ cells in SSc or pSS samples
compared with healthy controls, although there was a signif-
icant increase in SSc as compared with pSS. In the T-helper
subset, the prevalence of CD4 + CD28+ T-helper cells was
significantly lower in both SSc and pSS than in controls.
There was no difference in the prevalence of CD3 + CTLA-
4+ cells between the study groups, but within T-helper cells,
the amount of CD4 + CTLA-4+ T-helper cells was higher in
pSS compared with controls. The prevalence of CD3+ ICOS+
and CD4 + ICOS+ lymphocytes was higher in pSS than in
controls.
The frequency of CD3 + PD1+ and also CD4 + PD1+
lymphocytes was lower in both SSc and pSS samples than
in the controls (Fig. 2). Regarding the APCs (CD11b+ mono-
cytes), there was no difference observed in the prevalence of
CD80+, CD86+, and PD-L1 + expressingmonocytes between
SSc, pSS and healthy control samples. However, the frequen-
cy of ICOSL+ monocytes was lower in SSc than in controls,
and higher in pSS than in SSc.
No difference was observed in the prevalence of CD3+
IDO+ lymphocytes; however, IDO MFI values in CD3+ cells
were higher in pSS samples compared with controls (Fig. 3).
The prevalence of IDO+ monocytes was higher only in
pSS samples compared with controls, but there was no differ-
ence in the MFI of IDO in monocytes between the study
groups.
In order to explore the presence of reverse signaling via
CD80 and CD86, correlation analyses were performed. No
correlation was revealed between IDO-expressing T cells
and monocytes and the prevalence of CD80+ or CD86+
monocytes.
Table 2 Frequency of the investigated cell surface and intracellular markers
Healthy control
(n = 20)
SSc
(n = 9)
pSS
(n = 15)
CD3+ CD28+ cells/CD3+ lymphocytes 77.18 (65.78–82.50)% 84.73 (77.09–88.12)% 74.87b (60.60–77.43)%
CD3+ CD28+ CTLA-4+ cells/CD3+ CD28+ lymphocytes 8735 (6.463–11.73)% 9650 (7.920–10.09)% 11.60 (7.500–12.00)%
CD3+ ICOS+ cells/CD3+ lymphocytes 56.35 (50.36–74.92)% 74.24 (69.09–82.36)% 75.08a (73.09–77.34)%
CD3+ PD-1+ cells/CD3+ lymphocytes 49.83 (44.79–59.85)% 20.66a (15.00–34.42)% 17.43a (13.55–20.80)%
CD4+ CD28+ cells/CD4+ lymphocytes 97.82 (96.76–99.08)% 94.54a (87.38–96.85)% 94.54a (90.70–97.02)%
CD4+ CD28+ CTLA-4+ cells/CD4+ CD28+ lymphocytes 6340 (4565–8743)% 8060 (5785–9975)% 11.50a (9.660–12.60)%
CD4+ ICOS+ cells/CD4+ lymphocytes 59.05 (53.39–73.23)% 68.12 (64.87–72.95)% 74.11a (70.14–78.22)%
CD4+ PD-1+ cells/CD4+ lymphocytes 54.03 (47.89–62.85)% 17.45a (13.32–32.59)% 12.11a (7440–20.46)%
CD11b + CD80+ cells/CD11b + monocytes 54.22 (19.63–68.76)% 25.48 (22.75–33.12)% 29.32 (21.35–52.69)%
CD11b + CD86+ cells/CD11b + monocytes 27.57 (19.62–29.78)% 17.35 (13.21–22.52)% 27.47 (16.34–36.51)%
CD11b + PD-L1+ cells/CD11b + monocytes 74.09 (68.22–84.90)% 84.00 (51.43–86.79)% 82.40 (77.16–86.21)%
CD11b + ICOSL+ cells/CD11b + monocytes 61.23 (34.52–70.04)% 32.97a (27.93–44.23)% 59.81b (51.08–84.46)%
CD3+ IDO + cells/CD3+ lymphocytes 4500 (2615–7708)% 5430 (3785–7205)% 5170 (3730–6510)%
IDO MFI in CD3+ IDO + cells (arbitrary unit) 10,400
(7490–11,625)
20,737 (10,012–49,270) 17,857a(13,396–22,117)
CD11b + IDO + cells/CD11b + monocytes 2585 (1.970–10.84)% 6930 (4.365–13.40)% 18.46a (12.30–21.21)%
IDO MFI in CD11b + IDO + cells (arbitrary unit) 22,450
(19,875–24,475)
28,278 (11,670–37,101) 16,588 (12,338–28,590)
Data are presented as median (interquartile range)
CTLA-4 cytotoxic T lymphocyte antigen-4, ICOS inducible costimulator, PD-1 programmed death-1 receptor, PD-L1 programmed death-1 receptor
ligand, ICOSL inducible costimulator ligand, IDO indoleamine 2,3-dioxygenase, MFI mean fluorescence intensity
a Frequencies of cells isolated from SSc and pSS patients were compared with those of cells isolated from healthy individuals, p < 0.05
b Frequencies of cells isolated from pSS patients were compared with those isolated from SSc patients, p < 0.05
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Discussion
The key event in the development of an autoimmune disease
is the activation of effector CD4+ T cells that recognize a self
peptide. There are several checkpoints that must be overcome
to result in this, including the failure of central tolerance and
peripheral regulation. The presentation of autoantigens will
only initiate an autoimmune response if costimulatory signals
overcome the checkpoints of peripheral tolerance induction.
The aim of our study was to investigate the role of B7 family
molecules and IDO pathway molecules on monocytes and
their corresponding receptors on T lymphocytes in two sys-
temic autoimmune diseases. To the best of our knowledge, our
study is the first to investigate several members of
costimulatory molecules at the same time in pSS and SSc.
The B7 family is one of the most important second signal
mechanisms and is essential to the maintenance of the delicate
balance between immune potency and suppression of
autoimmunity. The importance of the B7 family in regulating
immune responses is clear from their demonstrated role in the
development of immunodeficiency, cancer, and autoimmune
diseases [22]. Manipulation of the signals delivered by B7
ligands shows a great potential in the treatment of cancer or
autoimmune disorders including pSS and SSc.
CD80/CD86, CD28, and CTLA-4
The upregulation of CD80/CD86 costimulatory molecules
and their corresponding receptor CD28 lead to an increase in
APC activity and the augmentation of T cell responses. In our
study, the expression of CD80 and CD86 costimulatory mol-
ecules was comparable in all three study groups. At the same
time, their corresponding receptor’s expression of CD28 was
lower in the T-helper subset both in pSS and SSc patients than
in controls. This finding indicates a decreased costimulation
via CD28 in T-helper cells in these diseases.
Fig. 2 Frequency of the investigated cell surface and intracellular
marker-positive cells. The expression of CD28 on T helper lymphocytes
and CD279 (PD-1) on T lymphocytes were lower in both SSc and pSS.
The frequency of CD152 (CTLA-4) in T helper lymphocytes and CD278
(ICOS) in T lymphocytes were increased in pSS but not in SSc. The
expression of CD275 (ICOSL) was strongly decreased in SSc on antigen
presenting cells. SSc systemic sclerosis, pSS primary Sjögren’s syndrome,
PD-1 programmed death-1 receptor, CTLA-4 cytotoxic T lymphocyte
antigen-4, ICOS inducible costimulator, ICOSL inducible costimulator
ligand. a Frequencies of cells isolated from SSc or pSS patients were
compared with those of cells isolated from healthy individuals,
p < 0.05. b Frequencies of cells isolated from pSS patients were compared
with those isolated from SSc patients, p < 0.05.
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Furthermore, in our study, the frequency of CTLA-4+ T-
helper cells was higher in pSS than in controls. CTLA-4 is
located on the same chromosomal region as CD28, and binds
B7 more strongly. The B7 signal blockade using a CTLA-4 Ig
construct leads to suppression of humoral and cell-mediated
immune responses. Multiple mechanisms for CTLA-4-
mediated immunosuppression include competition for CD28
binding and induction of suppressive intracellular signaling
pathways such as cytokine-dependent tryptophan catabolism
and upregulation of IDO in B7-expressing APCs [9, 23].
Furthermore, a rapidly developing fatal lymphoproliferation
and multisystemic autoimmunity was demonstrated in Ctla-
4−/− mice [24].
No biological agent has yet been approved either for pSS or
SSc. Abatacept is a fully human fusion molecule of IgG-Fc
and CTLA-4 that modulates CD28-mediated T cell
costimulation. Given the mechanism of action of abatacept
and the recognized role of APCs and T and B cells in pSS
and SSc, selective modulation of costimulation represents a
reasonable therapeutic option. In an open-label pilot study of
abatacept in active pSS, patients with recent onset of pSS and
high disease activity were monitored. During the intravenous
abatacept treatment, ESSDAI, ESSPRI, rheumatoid factor,
and IgG levels decreased significantly, and fatigue and
health-related quality of life improved significantly [16].
Abatacept also induces clinical improvement in patients with
severe and treatment-resistant diffuse SSc [15]. In our study,
the lower level of CD28 receptors on T-helper cells in pSS and
SSc and the higher level of CTLA-4+ T-helper cells in pSS
suggest a Bprotective^ status of costimulation between APCs
and T cells that reduces the T cell-dependent autoimmune
response. The enrolled patients with pSS and SSc in our study
were selected randomly from our outpatient clinic. All inves-
tigated patients with pSS or with SSc had a low disease activ-
ity according to ESSDAI, ESSPRI, mRSS, and EScSG activ-
ity indices, respectively. All patients had relatively long dis-
ease duration, and took immunosuppressive therapy. It may be
hypothesized that either the long disease duration (chronic
autoimmune process) or the long-term effect of immunosup-
pressive agents might have lead to the desensitization or lower
expression of CD28 receptors and higher level of CTLA-4 on
T-helper cells in pSS and SSc.
ICOS
We have demonstrated that in T lymphocytes, the expression
of ICOS, a stimulator of T cell activation, is elevated in pSS,
but not in SSc, while that of its corresponding costimulatory
Fig. 3 IDO expression is elevated in pSS samples. While no difference
was observed in IDO expression between SSc and pSS patients and
controls in CD3+ lymphocytes, the frequency of IDO-expressing APCs
was higher in pSS samples than in healthy controls. The intracellular IDO
content (mean fluorescence intensity) was higher in CD3+ lymphocytes
in pSS than in controls. There was no difference in intracellular IDO
content in APCs in SSc and pSS samples compared with healthy
controls. IDO indoleamine 2,3-dioxygenase, SSc systemic sclerosis, pSS
primary Sjögren’s syndrome, APCs antigen-presenting cells, MFI mean
fluorescence intensity. a Cells from pSS patients were compared with
healthy controls, p < 0.05.
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molecule, ICOSL, was strongly decreased in SSc compared to
controls. Therefore, this pathway appears to play a more dom-
inant role in pSS.
Accumulating evidence suggests that ICOS is instru-
mental in T cell-driven multi-organ inflammation in auto-
immune diseases [25]. ICOSL was found to be expressed
not only in APCs, but also in salivary gland epithelial
cells (SGECs) in pSS. These SGECs play an important
role in the differentiation of naive CD4+ T cells into fol-
licular helper T cells by the secretion of IL-6. Interactions
between ICOSL on SGECs and ICOS on follicular helper
T cells results in enhanced IL-21 secretion by follicular
helper T lymphocytes [26]. In another study, ICOSL ex-
pression by CD11c+ myeloid cells was associated with
enhanced T cell survival in the kidneys of lupus-prone
mice. Local activation of ICOS by CD11c+ myeloid cells
drives organ inflammation in lupus. These results suggest
an autoantibody-independent role for ICOS in self-
reactive T cell survival in target organs [27]. According
to these findings, our results point to a potential role of
ICOS in the pathomechanism of pSS, potentially by
means of the maintenance of a sustained stimulation of
T cells within the target organs, including the salivary
gland.
Similarly to our findings, a greater frequency of circulating
T follicular helper (Tfh) cells express ICOS in systemic lupus
erythematosus (SLE) compared to healthy controls.
Furthermore, in vitro ICOS costimulation of peripheral T cells
from patients with active SLE resulted in greatly enhanced
IFN-γ production relative to normal controls, and ICOS liga-
tion preferentially induced production of isotype-switched α-
double-stranded DNA (α-dsDNA) antibodies during co-
culture with autologous B cells. In animal models, splenic
ICOS+ CD4+ T cell production of IL-21 was linked to renal
disease and early mortality. In a different study, DC ICOSL
expression was correlated with kidney nephritis and protein-
uria. As a whole, byway of enhancing autoantibody formation
and accelerating organ inflammation, these data strongly sug-
gest that ICOS plays a direct role in promoting SLE disease
progression [28]. Therapeutic interventions designed to dis-
rupt ICOS/ICOSL signaling may therefore be similarly prom-
ising in pSS as in SLE, taking our current findings into
consideration.
PD-1
The frequency of PD-1 expressing T lymphocytes was found
to be decreased both in pSS and SSc compared with controls,
while there was no difference in the PD-L1 expression of
APCs between the investigated study groups.
PD-1 regulates self-tolerance against many organs and pre-
vents autoimmunity by setting at least two checkpoints that
control the induction and maintenance phases of the anergic
state. In addition, the innate immune system may inhibit
autoreactive lymphocyte proliferation by PD-1-induced path-
ways [29]. Decreased frequencies of PD-1 expressing T cells
may reflect deficiencies in this regulatory pathway in these
two connective tissue diseases.
IDO
There is abundant evidence of immune cell hyper-activation in
pSS and SSc. This raises the question of whether there is
corresponding activation of the IDO pathway, in an attempt
to regulate uncontrolled T cell responses. IDO is the first and
rate-limiting step in the KYN pathway, and is thought to play a
key role in immune homeostasis through depletion of trypto-
phan and accumulation of KYN metabolites. Inhibition of
IDO activity, or knockout of the gene encoding IDO, was
shown to cause an increase in the severity of collagen-
induced arthritis, an animal model of rheumatoid arthritis
[30]. On the other hand, a higher percentage of IDO-
expressing APCs was observed supported in pSS than in
healthy controls [31]. Increased KYN concentration and
KYN/TRP ratio, which reflects the activity of IDO, were also
measured in the peripheral blood of pSS patients [32]. In our
study, we found that the frequency of IDO-expressing APCs,
as well as intracellular IDO content in T cells, was higher in
pSS than in controls. Therefore, it is possible that the in-
creased IDO activity tries to control the chronic autoantigen
stimulation in pSS and plays a role in the counter-regulatory
response.
Our results also supported that the induction of IDO activ-
ity resulting in the activation of the KYN pathway is an attrac-
tive therapeutic approach. However, further investigation of
the downstream members of the KYN pathway is needed to
confirm or refute this hypothesis.
A limitation of our study is the lack of data on changes in
cytokine and chemokine expression related to alterations ob-
served in the costimulatory pathways. These linked mecha-
nisms also play a key role in the pathomechanism of pSS
and SSc and need further investigation based on the current
results. Another limitation may be the heterogeneity of our
patient populations in terms of treatment with different immu-
nosuppressive agents. In future studies, patients with more
active disease state should also be included.
Conclusion
Our understanding of the B7 family has expanded enormously
since the description of costimulatory pathways.
Contemporary models of immune regulatory networks reflect
this complexity. Defining the signals by which specific types
of APCs and costimulatory molecules drive T cell autoimmu-
nity, and elucidating whether these signals play a disease
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specific role, will advance our knowledge towards the devel-
opment of new therapeutics that rely on disrupting Tcell-APC
interactions. The promise of modification of autoimmune
mechanisms through pharmacologic manipulation of this
pathway shows substantial potential. Furthermore, our results
also suggest that the expression of costimulatory molecules
differs between distinct autoimmune disorders, although a
limitation of the current study is the low number of patients.
Therefore, sub-classification of the investigated patients’
group according to clinical characteristics (disease activity,
disease duration, medication, etc.) would provide further de-
tails about the role of costimulatory pathways.
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